Comparison
MGF (Mechano Growth Factor) vs. Survodutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Metabolic
CAS no.
12-Aminosäuren-C-terminales E-Domänen-Peptid (Sequenz nicht standardisiert)
2179963-22-7
Molecular weight
2867.2 g/mol
4727 g/mol
Half-life
0.1 h
168 h
Sequence
YQPPSTNKNTKSQRRKGSTFEERKmodifiziertes 29-Aminosäuren-Peptid mit FettsäureseitenketteMechanism of action
MGF (Mechano Growth Factor)
The IGF-1 gene produces multiple isoforms by alternative splicing. IGF-1Ec is upregulated after mechanical muscle loading; the C-terminal E-domain is cleaved from the mature IGF-1 protein and appears to have independent effects on satellite cells. The exact receptor binding of the E-domain is not established; a classical IGF-1R effect is unlikely since mature IGF-1 is responsible. In cell-culture studies, stimulation of myoblast proliferation and differentiation has been observed.
Survodutide
Survodutide is a dual agonist at the GLP-1 and glucagon receptors. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at high blood glucose and modulation of satiety. The glucagon component raises basal energy expenditure via hepatic and brown adipocyte effects. A fatty-acid side chain enables albumin binding and weekly dosing.
Evidence base
Highest evidence
Animal model
Human RCT
Studies
4
2
of which in humans
0
2
Effects recorded
3
3
Open conflicts
0
0
Documented adverse events
1
2